Exacerbations of chronic obstructive pulmonary disease (COPD) are associated with several modifiable (sedentary life-style, smoking, malnutrition, hypoxemia) and non-modifiable (age, co-morbidities, severity of pulmonary function, respiratory infections) risk factors. We hypothesise that most of these risk factors may have a converging and deleterious effects on both respiratory and peripheral muscle function in COPD patients. Methods: A multicentre study was carried out in 121 COPD patients (92% males, 63 AE 11 yr, FEV 1 , 49 AE 17%pred). Assessments included anthropometrics, lung function, body composition using bioelectrical impedance analysis (BIA), and global muscle function (peripheral muscle (dominant and non-dominant hand grip strength, HGS), inspiratory (PI max ), and expiratory (PE max ) muscle strength). GOLD stage, clinical status (stable vs. non-stable) and both current and past hospital admissions due to COPD exacerbations were included as covariates in the analyses. Results: Respiratory and peripheral muscle weakness were observed in all subsets of patients. Muscle weakness, was significantly associated with both current and past hospitalisations. adjusting by FEV 1 (PE max , OR Z 6.8, p < 0.01; PI max , OR Z 2.9, p < 0.05; HGSd, OR Z 2.4, and HGSnd, OR Z 2.6, p Z 0.05). Moreover, a significant increase in both respiratory and peripheral muscle weakness, after adjusting by FEV 1 , was associated with current acute exacerbations. Conclusions: Muscle dysfunction, adjusted by GOLD stage, is associated with an increased risk of hospital admissions due to acute episodes of exacerbation of the disease. Current exacerbations further deteriorate muscle dysfunction ª
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Introduction
Chronic obstructive pulmonary disease (COPD) is a relevant health problem in most developed countries due to its high prevalence and enormous costs, both direct and indirect, which generate a tremendous burden on healthcare systems. 1 In Spain, COPD affects about 9% of the adult population (40e70 years old) and is the fourth largest cause of hospital admission and death in this age group. 1, 2 The natural history of COPD implies a series of respiratory symptoms and periods of clinical exacerbation that decrease not only the quality of life but also life expectancy. 3 Exacerbation is clinically defined by worsened dyspnoea, worsened sputum volume and/or change in its colour, and new or worsened cough. 2 There is limited information describing the clinicalephysiological changes in patients admitted to hospital with an exacerbation of COPD. Although several groups of authors have studied the risk factors of exacerbation in relation to hospital readmission for COPD patients, no study has specifically focused on muscle dysfunction.
One of the frequent extrapulmonary manifestations of COPD is skeletal muscle dysfunction and wasting. 4 With increasing severity of disease, patients with COPD loose muscle bulk, especially in their thighs and upper arms. Over time, exercise endurance decreases in these patients and they complain of dyspnoea and leg discomfort with mild to moderate workload increases. 5 These symptoms curtail exercise capacity and compromise cardiac fitness, which further limits exercise tolerance, creating a vicious downward spiral that can eventually lead to generalised debility and immobility. 6 Skeletal muscle dysfunction contributes to reduce health status of patients with COPD and substantially increases the risk of mortality, independent of traditional markers of COPD mortality such as baseline lung function, age, and cigarette smoking. 7, 8 Encouragingly, early interventions with exercise programmes may restore some of the lost health status related to muscle dysfunction and increase patients' exercise tolerance and stamina. 9 It is clearly recognised that, whereas one group of COPD patients may rarely need hospital admission during exacerbations, other groups of patients are prone to multiple admissions. 2 There are a few of studies suggesting that inspiratory and expiratory muscle dysfunction could act as a modifiable risk factor of hospital admission in patients with COPD. Martínez-Llorens et al. 10 using a case-control study design showed that exacerbations of COPD associates with pronounced deleterious changes in skeletal muscle function in association with acute loss of muscle mass. In other setting, González et al. 11 clearly identified that respiratory muscle overload (defined as a high pressuretime index of the inspiratory muscles) as a risk factor of hospital readmission in a 1-year follow-up of a cohort of patients with moderate-to-severe COPD. We hypothesised that patients with higher risk for severe exacerbations have a limited ventilatory reserve and that respiratory muscle dysfunction underlies and negatively affects the balance between functional reserve and acute loading imposed by exacerbation. 12 We thus considered that (1) a greater respiratory muscle dysfunction can be present even at the stable clinical conditions in patients with greater risk for hospital admission, and (2) that global muscle involvement could be captured by measuring inspiratory, expiratory and peripheral muscle strength. To test these hypotheses, a multicentre study was performed in two subsets of COPD patients defined by their clinical stability (present or absent). In a post-hoc analysis, the history of hospital admissions (none, current, or multiple hospitalisations) was taken in account in the analyses.
Methods
This was a multicentre, cross-sectional study carried out over two consecutive years. The principles of the Declaration of Helsinki 13 were applied and all patients gave written informed consent to participate. The study was approved by the Ethics Committees at all the centres participating in the study.
Candidates were all patients with COPD assigned to two cohorts: 1) patients admitted to the hospital due to exacerbations of COPD, and 2) stable COPD patients that currently go to the hospital for their regular follow-up. Those subsets of patients were defined by their clinical stability (present or absent). In a post-hoc analysis, the history of hospital admissions (none, current, or multiple hospitalisations) was taken into account for the definition of study groups. Group 1 was composed of patients who attended regular hospital follow-up but had never required hospital admission. Group 2 included clinically stable COPD patients defined as three or more months from the last exacerbation with a history of multiple (three or more) hospital admissions during the last year. Group 3 was composed of patients admitted to hospital for the very first time with a physician diagnosis of an acute exacerbation of COPD. Finally, Group 4 included patients with acute exacerbation but admitted to the hospital on multiple (three or more) occasions. Only patients requiring level II admission that is hospitalisation in a medical ward but not in the ICU 14 were included in the study. In the latter two groups (3 and 4), a respiratory physiotherapist performed an early (<48 hours of admission) assessment that included: 1) body weight; 2) inspiratory and expiratory muscle strength (expressed as maximal expiratory and inspiratory mouth pressures, respectively); 3) peripheral muscle strength (measured by hand dynamometry) and 4) body composition (bioelectrical impedance analysis, expressed in both absolute and relative values). Conventional blood and biochemical analyses were also taken for all patients and all prescribed drugs were systematically recorded.
Exclusion criteria were as follows: pneumonia, infection from any other organ, left heart failure, previous myocardial infarction, previous or present pulmonary embolism, asthma or the need for ventilatory support. In addition, patients were excluded if they had chronic respiratory failure and relevant comorbidity. These were defined as the presence or suspicion of recent orthopaedic, medical, or surgical diseases that could affect muscle structure and function and introduce confusion factors into the analysis. Peripheral oedema, suspicion of ascites, hormonal therapy for causes other than hyperglycaemia associated with steroid therapy during admission, and history of chronic systemic steroid therapy were considered additional exclusion criteria Current smoking was not considered an exclusion criterion.
Measurements
Body weight (in kilograms) was assessed using officially approved floor scales (SECA, Berlin, Germany). Patients were weighed in light clothing, barefoot and with an empty bladder. Values were rounded to nearest 100 g. Height (in m) was measured using a wall-mounted stadiometer. Body mass index (BMI) was calculated with the formula weight/ height 2 (kg/m 2 ). To assess body compartments, bioelectrical impedance analysis (BIA) was performed using portable equipment (BODYSTAT Ò 1500, Bodystat LTD, Isle of Man, British Isles). Fat, muscle mass and total body water were determined and expressed as relative values to total body weight. Arterial blood was taken following conventional techniques. Gas analyses were performed (Beckman Coulter, Synchron Cx9Po, Germany). Forced spirometry (Sibel, Barcelona, Spain), static lung volumes, airway resistance, and carbon monoxide diffusing capacity (Masterlab, Jaeger, Würzburg, Germany) were assessed in all patients.
15e17 Inspiratory and expiratory muscle strength were assessed by determining maximal respiratory mouth pressures during voluntary manoeuvres. Patients were instructed to carry out maximal respiratory efforts with occluded airway. 18 Maximal inspiratory pressure (PI max ) was measured from pulmonary residual volume (RV), and maximal expiratory pressure (PE max ) from total lung capacity (TLC). The best value of three reproducible manoeuvres (difference <5%) was included in the analysis. (P max Morgan Medical, Gillingham, Kent, UK). PI max and PE max values were assessed both in absolute (cmH 2 O) and relative pressure values according to reference values reported by Morales and colleagues. 19 A hand dynamometer (JAMAR dynamometer; Preston, Jackson, MI, USA) was used to record maximal voluntary hand grip strength (HGS, in kg) of the finger flexors in both the dominant and non-dominant hand (HGS d and HGS nd respectively) during three consecutive manoeuvres separated by a 3-minute rest. The maximal value of the reproducible manoeuvres was used for the analysis. Absolute and relative values were analysed in relation to reference values. 20 
Statistical analysis
All numerical values are expressed as the mean AE SD. As a case control study the characteristics analysis was conducted using the t test (for quantitative variables of normal distribution), the KruskaleWallis test (for quantitative variables of non-normal distribution) or c 2 (for qualitative variables). Normal distribution was tested using a ShapiroeWilk test. The variables corresponding to muscle function and body composition were included in the analyses as dependent variables. Age and lung function tests were analysed as independent variables. An unconditioned multivariate logistic regression model was used to obtain the association between muscle weakness and exacerbation, after adjusting for potential confounders. 21 A p value of <0.05 was deemed to be significant.
Results
A total of 121 former or currently smoking patients (92% males) were included in the study. As part of the usual outpatient treatment, all patients received some inhaled bronchodilator therapy (formoterol, salmeterol, albuterol, tiotropium, ipratropium), 5% received oral theophylline, and 15% received inhaled steroids. No patient received systemic steroid therapy on a regular basis. At baseline, no patient presented chronic respiratory failure (defined as PaO 2 <60 mmHg), and none of them qualified for long-term oxygen therapy. Ten patients, however, showed PaCO 2 above 45 mmHg.
General characteristics of the study groups are summarised in Table 1 . Seventy-seven patients were at stable clinical conditions, whereas 44 patients were admitted to the hospital due to acute exacerbation of COPD. Differences in body composition were associated with history of multiple hospital admissions whereas patients under first hospital admission showed fat and fat-free mass comparable to the stable non admitted COPD group. Collectively, there were differences between the four groups in some principal pulmonary function variables. Patients with history of multiple admissions and present acute exacerbation, disclosed greater air trapping (%RV) and lower diffusing capacity for CO (both TL CO and K CO ) compared to the COPD patients without admissions (p < 0.05 each). Table 2 shows that muscle weakness was strongly associated with the past and current exacerbations of COPD. Fig. 1 shows a significant decrease of both respiratory and peripheral muscle strength in all patient groups. After adjusting by GOLD stage (FEV 1 ), muscle weakness showed a significant association with two covariates: number of past admissions and current hospital admission, as indicated in Tables 2e4.
Discussion
The present study confirms that dysfunction of both respiratory and peripheral muscles is highly prevalent in patients with COPD, even during stable clinical conditions. This is probably the first report identifying an association between risk for hospital admission due to exacerbations and baseline muscle function, irrespective of body weight and BMI.
This association between muscle weakness and risk of hospitalisation remained significantly increased after adjustment by the degree of airflow obstruction.
Muscle dysfunction in patients with COPD is not merely a cosmetic description. Muscle function is relevant from the clinical point of view as it is associated with increased symptoms (dyspnoea and discomfort in legs), impaired physical performance (e.g., decrease in exercise capacity), reduced health status, and increased risk of mortality, 2 independent of traditional markers of COPD mortality such as baseline lung function, age, and cigarette smoking.
6,7 Surprisingly, we identified one study analysing the potential role of muscle dysfunction as a risk factor of severe exacerbations of COPD and hospital admissions.
11
Our results reported so far suggested a previously unrecognised association in which muscle dysfunction is not only present in stable clinical conditions but associated with the risk of hospital admissions. The present multicentre study offers novel information, including a particular selection and group assignment of the patients. We analysed former smokers with COPD who showed a preserved body weight and were without comorbidity (known or detected during the clinical assessment processes), regular use of alcohol or sedatives, and domiciliary oxygen therapy. These selection criteria allow us to summarise the results in three main concepts, as follows. The first concept is that patients with stable COPD without hospital admissions had a high prevalence of respiratory and peripheral muscle dysfunction as assessed by strength of inspiratory, expiratory and peripheral muscles ( Table 2 ). These data confirm previous knowledge that skeletal muscle dysfunction is among the frequent extrapulmonary manifestations even in stable COPD. 4 The second concept derived from our study is that, acute exacerbation of COPD associates with an increase in both prevalence and severity of global muscle dysfunction (Table  4) . It is reasonable to postulate that this additional impairment in muscle function is associated with the inflammatory burst and therapy of exacerbations. In fact, we recently showed that COPD patients who require admission for exacerbation suffer a global, progressive and linear deterioration of muscle function. 10 The third concept deals with the evidence that prevalence and severity of respiratory and peripheral muscle dysfunction remain elevated even while recovering clinical stability (Table 3) . These data are consistent with the study from other cohort by Gonzalez et al., 11 who were able to demonstrate that at hospital discharge, noninvasively measured respiratory muscle overload were associated with an increased risk of hospital readmission for exacerbation in patients with moderate-to-severe COPD. Despite these information, the ultimate cause of muscle dysfunction has not yet been determined in either stable or exacerbated COPD, but our study clearly demonstrates that muscle weakness strongly associates with the risk for hospitalisation due to exacerbation, as discussed below.
Exacerbation of COPD represents not only a worsening of airflow obstruction but also increased respiratory and systemic demand in a host receiving treatment and with limited ventilatory reserve. 22 With regards to inspiratory Figure 1 The graph represents the proportion of patients suffering muscle dysfunction determined by a decrease under 70% of the predicted values. The prevalence of respiratory muscle dysfunction is higher in exacerbated patients but for peripheral muscles, the prevalence is more notorious in hospital multiple admitted patients. muscles, one of the factors related to functional deterioration during exacerbation is the progressive increase in functional residual capacity due to dynamic air trapping. 2 However, our study also demonstrates that the patients prone to hospitalisation showed a greater dysfunction of expiratory muscles (assessed as PE max ) and peripheral muscles (HGS), which cannot be explained by geometrical changes in the thorax. In addition, systemic inflammation is associated with reduced muscle strength, exercise tolerance, and health status in COPD patients 23 ; exacerbations have been associated with an inflammatory burst as assessed by increases in inflammatory mediators in both sputum and plasma. 4 A systemic (global) muscle involvement was captured in the present study by detecting both peripheral muscle weakness and modified fat free mass index in patients with higher risk of exacerbation. Peripheral muscle function (strength and endurance) is closely related to the absolute quantity of muscle mass, which is reduced with aging.
24e27
Consistent with a previous study, 30 however, and intrinsic to our selection criteria, we were unable to demonstrate a relationship between age, body weight or BMI, and susceptibility to multiple exacerbations. Prior retrospective studies have stated that a significant proportion of patients with COPD suffer from progressive weight loss in relation to exacerbation of their disease. 28 Other transversal studies in this field, such as one by Pascual and colleagues, 29 have shown that deterioration of pulmonary function has a correlation with some anthropometric variables in COPD patients. We should point out that our patients are from the Mediterranean area, whereas the study by Vermeeren and colleagues 28 included patients from the north of Europe. Consequently, we cannot exclude the possibility that there are differences in the impact of exacerbation of the disease on patients living in different geographical regions or having a different ethnic origin. 30 Similar differences have recently been described in cardiovascular disease with a multifactorial origin. 31 In summary, the present study adds a piece of information demonstrating that peripheral muscle function may be clinically useful as an additional marker of risk of exacerbation in patients with COPD, normal weight, and normal BMI.
One of the limitations of this study is that a crosssectional design does not allow us to identify causative relationships between muscle function and exacerbation or treatment. Previous studies reported that COPD exacerbation was associated with a progressive loss of water and muscle body mass that reached minimum values on the day of hospital discharge. 28 Other possible limitations could be related to the absence of functional assessments of lower limb muscles such as histological correlates, muscle or fat tissue biopsies and adipometric techniques. As for the physical exercise tests or limb muscle measurements, a practical and ethical limitation has made us restrict assessments to those that, in our opinion, would not involve a significant increase in metabolic waste. For similar reasons, we did not carry out biopsies of muscle or fat. Finally, we did not perform adipometric assessments or compartmental anthropometry. This limits us when defining whether the changes assessed with BIA had a peripheral, centripetal, or global distribution.
Conclusion
Collectively, the present results extend the concept of susceptibility to multiple exacerbations of COPD beyond the pulmonary system to the muscle compartments. We provide a clinical and epidemiological rationale linking inspiratory and expiratory muscle dysfunction with susceptibility to multiple exacerbations of COPD. Our study shows that muscle function may be clinically useful as a marker of exacerbation risk in patients with COPD.
These data support the possibility of using respiratory and peripheral muscle training as an additional treatment to mitigate the increased susceptibility to exacerbations. 
